

## LEGENDA

20 totaal  
scores

**30mg beter dan 15mg**  
**15mg beter dan 30mg**  
**Gelijk**

**14x**  
**3x**  
**3x**

**Relatief oplopend van 3% verschil tot 46%!! Vooral verschil in SELECT MONOTHERAPY en EARLY is groot**  
Relatief oplopend van 1% verschil tot 11%. In geen van de studies is de 15mg beter dan de 30mg.

### (1) SELECT-NEXT (who did not adequately respond to treatment with conventional synthetic DMARDs (csDMARDs))

#### Week 12

	ACR20	ACR50	ACR70	LDA	Cl. Rem.
15mg	64	38	21	48	31
30mg	66	43	27	48	28
<b>Vershil</b>	<b>-2</b>	<b>-5</b>	<b>-6</b>	<b>0</b>	<b>3</b>
in % relatief	-3%	-13%	-29%	0%	11%

### (2) SELECT-BEYOND (who did not adequately respond or were intolerant to treatment with biologic DMARDs (bDMARDs))

#### Week 24

	ACR20	ACR50	ACR70	LDA	Cl. Rem.
15mg	62	43	22	52	32
30mg	59	43	24	52	35
<b>Vershil</b>	<b>3</b>	<b>0</b>	<b>-2</b>	<b>0</b>	<b>-3</b>
in % relatief	5%	0%	-9%	0%	-9%

### (3) SELECT-EARLY (monotherapy treatment compared to MTX who were MTX-naïve)

#### Week 24

	ACR20	ACR50	ACR70	LDA	Cl. Rem.
15mg	79	60	44	60	48
30mg	78	66	50	65	50
<b>Vershil</b>	<b>1</b>	<b>-6</b>	<b>-6</b>	<b>-5</b>	<b>-2</b>
in % relatief	1%	-10%	-14%	-8%	-4%

(4) SELECT-COMPARE (who are on a stable background of MTX and had an inadequate response)

**GEEN VERGELIJK WEGENS ONTBREKEN 30mg**

(5) SELECT-MONOTHERAPY (monotherapy treatment compared to MTX who did not adequately respond to treatment with MTX)

**Week 14**

	<b>ACR20</b>	<b>ACR50</b>	<b>ACR70</b>	<b>LDA</b>	<b>Cl. Rem.</b>
15mg	68	42	23	45	28
30mg	71	52	33	53	41
<b>Vershil</b>	<b>-3</b>	<b>-10</b>	<b>-10</b>	<b>-8</b>	<b>-13</b>
in % relatief	-4%	-24%	-43%	-18%	-46%

<https://news.abbvie.com/news/abbvies-upadacitinib-abt-494-meets-all-primary-and-ranked-secondary-endpoints-in-phase-3-study-in-rheumatoid-arthritis.htm>

<https://news.abbvie.com/news/abbvies-upadacitinib-abt-494-meets-all-primary-and-ranked-secondary-endpoints-in-second-phase-3-study-in-rheumatoid-arthritis.htm>

<https://news.abbvie.com/news/upadacitinib-monotherapy-meets-all-primary-and-ranked-secondary-endpoints-versus-methotrexate-in-phase-3-study-in-rheumatoid-arthritis.htm>

<https://news.abbvie.com/news/upadacitinib-meets-all-primary-and-ranked-secondary-endpoints-including-superiority-versus-adalimumab-in-phase-3-study-in-rheumatoid-arthritis.htm>

<https://news.abbvie.com/news/abbvies-upadacitinib-shows-positive-results-as-monotherapy-in-phase-3-rheumatoid-arthritis-study-meeting-all-primary-and-key-secondary-endpoints.htm>